(ZEAL) Zealand Pharma - Ratings and Ratios

Zealand Pharma A/S is a biotechnology company specializing in the discovery, development, and commercialization of peptide-based therapies, addressing unmet medical needs in gastrointestinal and metabolic disorders, among other specialty disease areas. The companys product portfolio includes Zegalogue, a single-use treatment for severe hypoglycemia, and Dasiglucagon, used in bi-hormone artificial pancreas systems. Its pipeline features Dasiglucagon for congenital hyperinsulinism and glepaglutide, a long-acting GLP-2 analog in Phase III trials for short bowel syndrome. Zealand Pharma A/S, founded in 1997, is headquartered in Søborg, Denmark.

Based on the provided data, Zealand Pharma A/S is expected to face a challenging 3-month outlook. Technically, the stock is trading below its 20, 50, and 200-day moving averages (SMA 20: 482.84, SMA 50: 588.45, SMA 200: 759.09), indicating bearish momentum. The Average True Range (ATR) of 42.67 suggests moderate volatility. Fundamentally, with a high P/S ratio of 482.19 and a negative Return on Equity (RoE) of -12.52, the companys valuation reflects high expectations for future growth, likely tied to its pipeline progress. However, near-term price movement may remain subdued due to technical resistance levels and ongoing losses.